Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
On 25 June 2026, the drug maker informed the exchanges that the US Food and Drug Administration (USFDA) had completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection was conducted between 16 June 2026 and 25 June 2026.
Following the inspection, the USFDA issued a Form 483 with seven observations. Dr. Reddy's said it will respond to the observations within the stipulated timeline.
The company said the inspection is a continuation of earlier inspections and related disclosures made to the stock exchanges on 12 October 2023 and 13 September 2025.
Hyderabad-based Dr Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
The company reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.
Previously, the USFDA had conducted a Pre-Approval Inspection (PAI) at the same Hyderabad facility between 4 September and 12 September 2025, following which it had issued five observations.
Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
The counter advanced 1.63% to settle at Rs 1,350 on Thursday, 25th June 2026. The NSE and BSE remain closed today on account of Muharram.
Dr Reddys Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1350.6, up 1.67% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.71% on the day, quoting at 24192.85. The Sensex is at 77548.16, up 0.72%. Dr Reddys Laboratories Ltd has added around 1.71% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 1.66% in last one month and is currently quoting at 25018.95, up 0.2% on the day. The volume in the stock stood at 10.78 lakh shares today, compared to the daily average of 15.46 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1353.9, up 2.07% on the day. Dr Reddys Laboratories Ltd is up 2.2% in last one year as compared to a 5.31% fall in NIFTY and a 14.95% fall in the Nifty Pharma index.
The PE of the stock is 34.44 based on TTM earnings ending March 26.
The pharmaceutical major has collaborated with MSN Laboratories (MSN), a leading pharmaceutical company in India, on this product.
Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.
Bosutinib Tablets was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S.
The Bosulif brand had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.
Milan Kalawadia, CEO- North America, Dr. Reddy’s Laboratories, Inc. said: 'This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers.
With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.'
The company had reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.
The scrip shed 0.09% to end at Rs 1273.90 on the BSE on Friday.
Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1274.9, down 1.2% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.36% on the day, quoting at 23467.1. The Sensex is at 74624.13, up 0.48%.Dr Reddys Laboratories Ltd has lost around 0.96% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 1.87% in last one month and is currently quoting at 24214.25, down 1.23% on the day. The volume in the stock stood at 12.03 lakh shares today, compared to the daily average of 26.7 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1284, down 0.89% on the day. Dr Reddys Laboratories Ltd jumped 2.13% in last one year as compared to a 4.38% slide in NIFTY and a 11.99% spurt in the Nifty Pharma index.
The PE of the stock is 33.42 based on TTM earnings ending March 26.
Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on 28 April 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy's readiness to ensure patient access following approval.
In Canada, Dr. Reddy's Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.
Securities in F&O Ban:
Steel Authority of India are banned from F&O trading on 13 May 2026.
Result Today:
Balaji Amines, The Bombay Burmah Trading Corporation, Bharti Airtel, Bharti Hexacom, CARE Ratings, Cipla, Crompton Greaves Consumer Electricals, DCM Shriram, DLF, eClerx Services, GlaxoSmithKline Pharmaceuticals, Hindustan Petroleum Corporation, Inventurus Knowledge Solutions, Interarch Building Solutions, JSW Dulux, Kaynes Technology India, Kirloskar Brothers, LIC Housing Finance, Man Infraconstruction, Metropolis Healthcare, NLC India, Oil Indi, Onesource Specialty Pharma, Paras Defence and Space Technologies, Power Finance Corporation, Quality Power Electrical Equipments, Redington, Sagar Cements, Sharda Cropchem, Signatureglobal (India), SKF India, Suven Life Sciences, Tourism Finance Corporation of India, Tube Investments of India, Tata Motors, TVS Holdings, TVS Motor Company, Zaggle Prepaid Ocean Services and ZF Commercial Vehicle Control Systems India
Stocks to Watch:
Dr. Reddy's Laboratories reported an 86.14% decline in consolidated net profit to Rs 220.9 crore on an 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 compared with Q4 FY25.
Berger Paints India reported a 27.9% rise in consolidated net profit to Rs 335 crore from Rs 262 crore. Revenue increased 6.1% to Rs 2,868 crore from Rs 2,704 crore.
Dixon Technologies (India) reported a 35.91% decline in consolidated net profit to Rs 297.97 crore on a 2.12% increase in revenue from operations to Rs 10,510.51 crore in Q4 FY26 compared with Q4 FY25.
Neuland Laboratories reported a 665.1% jump in consolidated net profit to Rs 212.7 crore from Rs 27.8 crore. Revenue rose 134.8% to Rs 788.7 crore from Rs 335.8 crore.
Tata Power reported a 4.5% decline in consolidated net profit to Rs 996 crore from Rs 1,043 crore. Revenue fell 12.9% to Rs 14,900 crore from Rs 17,096 crore.
Torrent Power reported a 70% decline in consolidated net profit to Rs 318 crore from Rs 1,059 crore. Revenue slipped 0.8% to Rs 6,406 crore from Rs 6,456 crore.
Thomas Cook (India) reported a 40.1% decline in consolidated net profit to Rs 38.7 crore from Rs 64.6 crore. Revenue fell 10.1% to Rs 1,771 crore from Rs 1,969 crore.
Kalpataru reported a consolidated net profit of Rs 200 crore compared with Rs 14.1 crore a year ago. Revenue surged 183.7% to Rs 1,694 crore from Rs 597 crore.